Safe Nanocomposite-Mediated Efficient Delivery of MicroRNA Plasmids for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapy

Yen Chang Tsai, I. Ling Teng, Si Tse Jiang, Yi Che Lee, Yuan-Yow Chiou, Fong Yu Cheng

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

There is currently no cure for gene mutation-caused autosomal dominant polycystic kidney disease (ADPKD). Over half of patients with ADPKD eventually develop kidney failure, requiring dialysis or kidney transplantation. Current treatment modalities for ADPKD focus on reducing morbidity and mortality from renal and extrarenal complications of the disease. MicroRNA has been shown to be useful in treating ADPKD. This study combines anti-miRNA plasmids and iron oxide/alginate nanoparticles for conjugation with antikidney antibodies. These nanocomposites can specifically target renal tubular cells, providing a potential treatment for ADPKD. Magnetic resonance imaging and in vivo imaging system results show effective targeting of renal cells. Anti-miRNA plasmids released from the nanocomposites inhibit cell proliferation and cyst formation in the PKD cellular and animal models. The results suggest the novel combination of the anti-miRNA plasmids and nanomaterials provides potential clinical implications for ADPKD treatment.

Original languageEnglish
Article number1801358
JournalAdvanced Healthcare Materials
Volume8
Issue number5
DOIs
Publication statusPublished - 2019 Mar 7

Fingerprint

Autosomal Dominant Polycystic Kidney
Nanocomposites
MicroRNAs
Plasmids
Kidney
Therapeutics
Nanostructures
Dialysis
Alginate
Kidney Transplantation
Nanoparticles
Cell proliferation
Renal Insufficiency
Cysts
Iron oxides
Nanostructured materials
Antibodies
Imaging systems
Magnetic resonance imaging
Animal Models

All Science Journal Classification (ASJC) codes

  • Biomaterials
  • Biomedical Engineering
  • Pharmaceutical Science

Cite this

@article{42d2b32b728b468aaf9e21f488cb030f,
title = "Safe Nanocomposite-Mediated Efficient Delivery of MicroRNA Plasmids for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapy",
abstract = "There is currently no cure for gene mutation-caused autosomal dominant polycystic kidney disease (ADPKD). Over half of patients with ADPKD eventually develop kidney failure, requiring dialysis or kidney transplantation. Current treatment modalities for ADPKD focus on reducing morbidity and mortality from renal and extrarenal complications of the disease. MicroRNA has been shown to be useful in treating ADPKD. This study combines anti-miRNA plasmids and iron oxide/alginate nanoparticles for conjugation with antikidney antibodies. These nanocomposites can specifically target renal tubular cells, providing a potential treatment for ADPKD. Magnetic resonance imaging and in vivo imaging system results show effective targeting of renal cells. Anti-miRNA plasmids released from the nanocomposites inhibit cell proliferation and cyst formation in the PKD cellular and animal models. The results suggest the novel combination of the anti-miRNA plasmids and nanomaterials provides potential clinical implications for ADPKD treatment.",
author = "Tsai, {Yen Chang} and Teng, {I. Ling} and Jiang, {Si Tse} and Lee, {Yi Che} and Yuan-Yow Chiou and Cheng, {Fong Yu}",
year = "2019",
month = "3",
day = "7",
doi = "10.1002/adhm.201801358",
language = "English",
volume = "8",
journal = "Advanced healthcare materials",
issn = "2192-2640",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

Safe Nanocomposite-Mediated Efficient Delivery of MicroRNA Plasmids for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapy. / Tsai, Yen Chang; Teng, I. Ling; Jiang, Si Tse; Lee, Yi Che; Chiou, Yuan-Yow; Cheng, Fong Yu.

In: Advanced Healthcare Materials, Vol. 8, No. 5, 1801358, 07.03.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safe Nanocomposite-Mediated Efficient Delivery of MicroRNA Plasmids for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapy

AU - Tsai, Yen Chang

AU - Teng, I. Ling

AU - Jiang, Si Tse

AU - Lee, Yi Che

AU - Chiou, Yuan-Yow

AU - Cheng, Fong Yu

PY - 2019/3/7

Y1 - 2019/3/7

N2 - There is currently no cure for gene mutation-caused autosomal dominant polycystic kidney disease (ADPKD). Over half of patients with ADPKD eventually develop kidney failure, requiring dialysis or kidney transplantation. Current treatment modalities for ADPKD focus on reducing morbidity and mortality from renal and extrarenal complications of the disease. MicroRNA has been shown to be useful in treating ADPKD. This study combines anti-miRNA plasmids and iron oxide/alginate nanoparticles for conjugation with antikidney antibodies. These nanocomposites can specifically target renal tubular cells, providing a potential treatment for ADPKD. Magnetic resonance imaging and in vivo imaging system results show effective targeting of renal cells. Anti-miRNA plasmids released from the nanocomposites inhibit cell proliferation and cyst formation in the PKD cellular and animal models. The results suggest the novel combination of the anti-miRNA plasmids and nanomaterials provides potential clinical implications for ADPKD treatment.

AB - There is currently no cure for gene mutation-caused autosomal dominant polycystic kidney disease (ADPKD). Over half of patients with ADPKD eventually develop kidney failure, requiring dialysis or kidney transplantation. Current treatment modalities for ADPKD focus on reducing morbidity and mortality from renal and extrarenal complications of the disease. MicroRNA has been shown to be useful in treating ADPKD. This study combines anti-miRNA plasmids and iron oxide/alginate nanoparticles for conjugation with antikidney antibodies. These nanocomposites can specifically target renal tubular cells, providing a potential treatment for ADPKD. Magnetic resonance imaging and in vivo imaging system results show effective targeting of renal cells. Anti-miRNA plasmids released from the nanocomposites inhibit cell proliferation and cyst formation in the PKD cellular and animal models. The results suggest the novel combination of the anti-miRNA plasmids and nanomaterials provides potential clinical implications for ADPKD treatment.

UR - http://www.scopus.com/inward/record.url?scp=85060519756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060519756&partnerID=8YFLogxK

U2 - 10.1002/adhm.201801358

DO - 10.1002/adhm.201801358

M3 - Article

VL - 8

JO - Advanced healthcare materials

JF - Advanced healthcare materials

SN - 2192-2640

IS - 5

M1 - 1801358

ER -